GlassScriptPhysician profile
Margaret Coe
NPI 1366997520
$11,933.22
in general payments reported to CMS, 2019-2025
45 companies · $2,103 in 2025
The $2,103 reported for 2025 was more than what 92% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,219 · 2022: $2,596 · 2023: $2,846 · 2024: $2,169 · 2025: $2,103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,027 · Education: $90.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,027.33 |
| Education | $90.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,919.08 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $904.01 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $723.22 | 2021-2025 | |
| Amgen INC. | $704.10 | 2021-2025 | Otezla, Repatha, Otezla |
| Lilly USA, LLC | $694.61 | 2021-2024 | Emgality, Mounjaro, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $675.28 | 2022-2025 | |
| Novo Nordisk INC | $659.32 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $652.82 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $434.03 | 2021-2025 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $363.25 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $352.56 | 2021-2024 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $335.37 | 2021-2025 | Trintellix, Eohilia |
| Axsome Therapeutics, INC. | $302.10 | 2022-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $283.83 | 2021-2024 | Austedo Xr, Austedo |
| Novartis Pharmaceuticals Corporation | $281.30 | 2021-2023 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $270.05 | 2024-2025 | Fanapt |
| Biohaven Pharmaceutical Holding Company LTD. | $213.95 | 2022 | |
| Janssen Pharmaceuticals, INC | $212.61 | 2022-2024 | Spravato |
| Alkermes, INC. | $179.73 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Paratek Pharmaceuticals, INC. | $174.35 | 2021-2025 | Nuzyra |
| Lundbeck LLC | $149.06 | 2021-2025 | Rexulti |
| Glaxosmithkline, LLC. | $148.97 | 2021-2025 | Trelegy Ellipta |
| Neurocrine Biosciences, INC. | $129.25 | 2023-2025 | Ingrezza |
| Mylan Specialty L.P. | $120.81 | 2021-2023 | Yupelri |
| Idorsia Pharmaceuticals US INC | $104.10 | 2022-2023 | Quviviq |
| Exact Sciences Corporation | $102.00 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $95.42 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Nestle Healthcare Nutrition INC. | $82.42 | 2021-2023 | |
| Aimmune Therapeutics, INC. | $79.73 | 2024-2025 | Zenpep |
| Corcept Therapeutics | $55.73 | 2025 | Korlym |
| Supernus Pharmaceuticals, INC. | $53.58 | 2021-2024 | Qelbree |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.11 | 2021-2025 | Xifaxan |
| Shield Therapeutics INC | $46.95 | 2023-2024 | Accrufer |
| Optinose US, INC. | $46.33 | 2024 | |
| Ucb, INC. | $45.99 | 2024 | Nayzilam |
| Sunovion Pharmaceuticals INC. | $43.05 | 2022 | |
| Grt US Holding, INC. | $40.58 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $39.90 | 2021 | |
| Astellas Pharma US INC | $33.60 | 2023-2024 | Veozah |
| Phathom Pharmaceuticals, INC. | $32.53 | 2024-2025 | Voquezna |
| Dexcom, INC. | $31.87 | 2023-2025 | Dexcom G6 Transmitter |
| Actelion Pharmaceuticals US, INC. | $20.82 | 2024 | Opsumit, Uptravi |
| Allergan, INC. | $16.86 | 2022 | |
| Seqirus USA INC | $15.37 | 2022 | |
| Currax Pharmaceuticals LLC | $14.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margaret Coe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.